Search for an orphan drug
Other search option(s)
Marketing authorisation with orphan designation - USA
- Tradename: DACOGEN
- ATC code : -
- EU Number: -
- MA date : 02/05/2006
- MA holder: EISAI INC.
Therapeutic indication
For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Diseases list
Appraisal/reimbursement
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.